Biotech 2050 Podcast

Biotech 2050 Podcast

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

Denne podkasten er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(261)

Engaging the immune system against disease, Andrew Allen, Co-Founder, President & CEO, Gritstone bio

Engaging the immune system against disease, Andrew Allen, Co-Founder, President & CEO, Gritstone bio

Synopsis: Andrew Allen is the Co-Founder, President and CEO of Gritstone bio, a clinical-stage biotech company developing groundbreaking immunotherapies for cancers and infectious diseases such as C...

8 Feb 202347min

Novel approach to targeted protein degradation, Nicki Thompson, CEO, Amphista Therapeutics

Novel approach to targeted protein degradation, Nicki Thompson, CEO, Amphista Therapeutics

Synopsis: Nicki Thompson is the CEO of Amphista Therapeutics, a company identifying and advancing novel approaches in targeted protein degradation to develop a new generation of innovative therapies....

1 Feb 202333min

Envisioning people focused clinical trials, Michael Rosenblatt, VP of Clinical Operations, Roche

Envisioning people focused clinical trials, Michael Rosenblatt, VP of Clinical Operations, Roche

Disclaimer: Anything that is express in the following conversation are Michael's views and not necessarily those of Roche / Genentech. Synopsis: Michael Rosenblatt is the Vice President of Clinical...

25 Jan 202326min

Power of RNA to restore healthy gene expression, Josh Mandel-Brehm, President & CEO, CAMP4 Tx

Power of RNA to restore healthy gene expression, Josh Mandel-Brehm, President & CEO, CAMP4 Tx

Synopsis: Josh Mandel-Brehm is the President and CEO of CAMP4 Therapeutics, a company pioneering mRNA amplification by using programmable ASO therapeutics to control gene expression. He joins host Ra...

18 Jan 202329min

JPM23 Special: Rare diseases, Eslie Dennis, Kyowa Kirin, Arthur Suckow, DTx, & James Mackay, Aristea

JPM23 Special: Rare diseases, Eslie Dennis, Kyowa Kirin, Arthur Suckow, DTx, & James Mackay, Aristea

Synopsis: This special episode features a panel discussion with three biotech leaders about drug development for rare diseases. James Mackay, Ph.D., is the Founder, President and CEO of Aristea Ther...

11 Jan 202336min

JPM23 Special: Redefining cystic fibrosis treatment, Mike Cloonan, Pres. & CEO, Sionna Tx

JPM23 Special: Redefining cystic fibrosis treatment, Mike Cloonan, Pres. & CEO, Sionna Tx

Synopsis: Mike Cloonan is the President and CEO of Sionna Therapeutics, a life sciences company dedicated to developing therapies for people living with cystic fibrosis. They are developing first-in...

10 Jan 202325min

JPM23 Special: Advancing RNA Therapeutics, Geoff Nosrati, CBO, Nutcracker Therapeutics

JPM23 Special: Advancing RNA Therapeutics, Geoff Nosrati, CBO, Nutcracker Therapeutics

Synopsis: Geoff Nosrati is the Chief Business Officer of Nutcracker Therapeutics, an early-stage company that is pioneering a revolutionary therapeutic development and manufacturing platform designe...

9 Jan 202325min

133. Pharma & Profits, John LaMattina, former Pres. of R&D, Pfizer, Senior Partner, PureTech Health

133. Pharma & Profits, John LaMattina, former Pres. of R&D, Pfizer, Senior Partner, PureTech Health

Synopsis: John LaMattina is the former President of Global R&D at Pfizer and is currently a Senior Partner at PureTech Health. A self-proclaimed defender of the pharmaceutical industry, Dr. LaMattin...

4 Jan 202333min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
rekommandert
liberal-halvtime
sinnsyn
jss
villmarksliv
forskningno
tomprat-med-gunnar-tjomlid
fjellsportpodden
dekodet-2
rss-kunstig-intelligens-med-elisabeth-maren-og-morten
rss-rekommandert
nevropodden
smart-forklart
rss-paradigmepodden
rss-nysgjerrige-norge
abid-nadia-skyld-og-skam
abels-tarn
vett-og-vitenskap-med-gaute-einevoll